

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

[Find a Specialist](#) [Cancer & Treatment](#)

[Learn About Cancer & Treatment](#)

## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

## FOR THE MEDIA



## Sarat Chandarlapaty, MD, PhD

[Breast Medical Oncologist](#) ([#about-me](#))



### Areas of Expertise

#### Conditions I Treat

- Breast cancers and conditions

#### My Specialties

- Antibody therapy
- Immunotherapy
- Targeted therapy

 [Dr. Chandarlapaty's Office Information \(#contact-and-location\)](#)



Languages: English

## Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 646-497-9064](#)

[Make an appointment](#)

## Get to Know Me

I am a medical oncologist with a practice devoted to treating people with breast cancer.

I chose to focus on oncology because cancer is an enormous human problem and I wanted to help people who are affected by it. It has been my long-term desire to translate scientific discoveries into ways to treat disease and alleviate suffering.

Read more +

### What I Do at MSK

I'm a breast medical oncologist, which is a cancer doctor who specializes in breast cancer.

- Naddisy Foundation Chair in Breast Cancer Research at Memorial Sloan Kettering

## Areas of Expertise

### Conditions I Treat

- Breast cancers and conditions

### My Specialties

- Antibody therapy
- Immunotherapy
- Targeted therapy

## Education & Honors

### Education

- MD, Wake Forest University School of Medicine
- PhD, University of North Carolina at Chapel Hill (Biochemistry)

### Residencies

- Internal Medicine - New York Presbyterian Hospital

### Fellowships

- Hematology/Medical Oncology - Memorial Sloan Kettering Cancer Center

### Board Certifications

- Internal Medicine
- Medical Oncology

### Awards and Honors

- Castle Connolly: America's Top Doctor (2026)
- Castle Connolly: America's Top Doctor (2025)
- Castle Connolly: Top AAPI Doctor (2024)
- Castle Connolly: America's Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)

## Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176) .

# Make an Appointment

## New Patients

Scheduling an appointment is easy. Click or call [646-497-9064](tel:646-497-9064) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

## Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

# Contact and Location

## Office Phone

 [646-888-4311](tel:646-888-4311)

## Location

 New York, NY

### [Evelyn H. Lauder Breast Center](#)

 300 East 66th Street  
Floors 1 - 4  
New York, NY 10065

[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .

## Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. I work closely with nurse practitioner Bryn Vandermark and nurse Emer Heaney. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.

[See all Breast Medicine Service doctors](https://www.mskcc.org/doctor#f:Departments=[Medicine,Division of Solid Tumor Oncology,Breast Medicine Service]) ([https://www.mskcc.org/doctor#f:Departments=\[Medicine,Division of Solid Tumor Oncology,Breast Medicine Service\]](https://www.mskcc.org/doctor#f:Departments=[Medicine,Division of Solid Tumor Oncology,Breast Medicine Service]))

## Clinical Trials



### Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials](https://www.mskcc.org/cancer-care/clinical-trials) (<https://www.mskcc.org/cancer-care/clinical-trials>)

## Research and Publications

[View Dr. Chandarlapaty's Lab](#)

Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. *Cancer Cell*. 2011 Jan 18;19(1):58-71. doi: 10.1016/j.ccr.2010.10.031. Epub 2011 Jan 6. PMID: 21215704; PMCID: PMC3025058.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. *Nat Genet*. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3.

PMID: 24185512; PMCID: PMC3903423.

Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S. Activating *ESR1* Mutations Differentially Affect the Efficacy of ER Antagonists. *Cancer Discov.* 2017 Mar;7(3):277-287. doi: 10.1158/2159-8290.CD-15-1523. Epub 2016 Dec 16. PMID: 27986707; PMCID: PMC5340622.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. *Cancer Cell.* 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. PMID: 30537512; PMCID: PMC6294301.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in *PTEN* and *ESR1* promote clinical resistance to alpelisib plus aromatase inhibitors. *Nat Cancer.* 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. PMID: 32864625; PMCID: PMC7450824.

Li Q, Jiang B, Guo J, Shao H, Del Priore IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian AS, Rees MG, Ronan MM, Roth JA, Donovan KA, Palafox M, Reis-Filho JS, de Stanchina E, Fischer ES, Rosen N, Serra V, Koff A, Chodera JD, Gray NS, Chandarlapaty S. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. *Cancer Discov.* 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20. PMID: 34544752; PMCID: PMC8831444.

## Publications on PubMed

Visit PubMed for a full listing of Dr. Chandarlapaty's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed \(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Chandarlapaty%20S%5BAU%5D%20NOT%20Chandarlapaty%20SK%5BAU%5D\)](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Chandarlapaty%20S%5BAU%5D%20NOT%20Chandarlapaty%20SK%5BAU%5D)

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Sarat Chandarlapaty discloses the following relationships and financial interests:

- AstraZeneca  
Professional Services and Activities
- Casdin Capital, LLC  
Professional Services and Activities
- Daiichi Sankyo  
Professional Services and Activities
- Eli Lilly and Company  
Professional Services and Activities
- Encore Medical Education  
Professional Services and Activities
  
- Nuvalent, Inc.  
Professional Services and Activities
- Pathos AI, Inc.  
Equity; Professional Services and Activities
- Springer Nature Limited  
Professional Services and Activities
- Totus Medicines Inc.  
Equity

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center